– USA, NY – Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Dagmar Rosa-Bjorkeson to its Board of Directors as of April 1, 2021.
“Dagmar brings a wealth of insight and experience to the Intercept team and we are very pleased to welcome her to our Board,” said Jerry Durso, President and Chief Executive Officer of Intercept. “I’m looking forward to working with Dagmar during this pivotal year for the Company as we focus on enhancing our foundational PBC business, supporting our NASH regulatory process in the United States and Europe, and building our pipeline.”
About Dagmar Rosa-Bjorkeson
Ms. Rosa-Bjorkeson has more than 25 years of global experience in the pharmaceutical industry, including executive leadership positions in corporate and product strategy, market development, and operational execution. She is currently the COO of Mesoblast Limited. Ms. Rosa-Bjorkeson has led multiple successful product launches, including Gilenya for multiple sclerosis at Novartis where she was VP and Head of its multiple sclerosis business unit, VP, Business Development and Licensing in the United States, and Country Head and President for Novartis Sweden. Before joining Mesoblast, Ms. Rosa-Bjorkeson served as EVP and President, Biosimilars, at Baxalta, now a wholly-owned subsidiary of Takeda Pharmaceutical Company. She was also EVP and Chief Strategy and Development Officer at Mallinckrodt Pharmaceuticals.
“Intercept has a strong foundation, with differentiated science and commercial capabilities, and I believe the company has a unique opportunity to capitalize on its leadership position in progressive non-viral liver disease to deliver tremendous value for shareholders, the healthcare community, and, most importantly, patients in need,” said Ms. Rosa-Bjorkeson.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis and nonalcoholic steatohepatitis. Founded in 2002 in New York, Intercept has operations in the United States, Europe, and Canada.
For more information: https://www.interceptpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
